Search - tctmd.com

Displaying 121 - 140 of 294

Sort: Relevancy | Date

Presentation

Evolution of Practice During the IMS III Trial and Implications for Ongoing Trials

Presenter: Joseph P. Broderick

October 22, 2014

Presentation

Atrial Fibrillation, Stroke, and Mortality Rates Following TAVI

Presenter: Lior Yankelson

October 13, 2014

Presentation TCT 2014

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Presenter: John M. Lasala, Stuart J. Pocock, George Hanzel, MD

September 16, 2014

Presentation TCT 2014

Against the Proposal!

Presenter: Tudor G. Jovin

September 14, 2014

Presentation TCT 2014

For the Proposal!

Presenter: Philip M. Meyers

September 14, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation

Trends in Hospitalization and Outcomes for Acute CVD and Stroke, 1999-2011

Presenter: Harlan M. Krumholz

August 29, 2014

Presentation

Cryptogenic Stroke and Underlying A-fib

Presenter: Tomasso Sanna

July 01, 2014

Presentation

A-fib in Patients with Cryptogenic Stroke or TIA

Presenter: D.J. Gladstone

July 01, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

Presentation

National Trends in Stroke after AMI: 1999-2010

Presenter: Y. Wang

June 27, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

Presentation TVT 2014

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Presenter: Axel Linke

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will Become the Standard of Care

Presenter: Eberhard Grube

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Has Stroke Frequency Declined After TAVR?

Presenter: Nicolas M. van Mieghem

June 07, 2014

Presentation TVT 2014

Perspectives from the US CoreValve Trials

Presenter: Jeffrey J. Popma

June 07, 2014

Presentation TVT 2014

Perspectives from the PARTNER Trials

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Presenter: Samir R. Kapadia

June 07, 2014

Advertisement

Evolution of Practice During the IMS III Trial and Implications for Ongoing Trials

Atrial Fibrillation, Stroke, and Mortality Rates Following TAVI

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Against the Proposal!

For the Proposal!

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Trends in Hospitalization and Outcomes for Acute CVD and Stroke, 1999-2011

Cryptogenic Stroke and Underlying A-fib

A-fib in Patients with Cryptogenic Stroke or TIA

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

National Trends in Stroke after AMI: 1999-2010

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Why Cerebral Protection after TAVR Will Become the Standard of Care

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Has Stroke Frequency Declined After TAVR?

Perspectives from the US CoreValve Trials

Perspectives from the PARTNER Trials

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content